Skip to main content
OpenTrials
Completed

NCT Number: NCT01845311

ReZolve2 Clinical Investigation

The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2 Bioresorbable Coronary Scaffold in native coronary arteries.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St Vincent's Hospital, Sydney, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Primary Inclusion Criteria:

  • Patient has evidence of myocardial ischemia or a positive functional study
  • Patient has a normal CK-MB
  • Target lesion has a visually estimated stenosis of ≥50% and <100%
  • Target lesion is located in a native coronary artery with average reference vessel diameter ≥ 2.75mm and ≤ 3.3mm
  • Target lesion length must be ≤ 14mm

Primary Exclusion Criteria:

  • Patient has experienced a myocardial infarction (CK-MB or Troponin > 5 X ULN) within 72 hours of the procedure
  • Patient has a left ventricular ejection fraction < 30%
  • Patient has unprotected lest main coronary disease with ≥50% stenosis
  • The target vessel is totally occluded (TIMI Flow 0 or 1)
  • Target lesion involves a bifurcation (a lesion with a side branch ≥ 2.0 mm in diameter containing a ≥ 50% stenosis).
  • Target lesion is located within a bypass graft
  • Target lesion has possible or definite thrombus

Treatment and study plan

ReZolve2 Scaffold

Device

Primary outcomes

  1. Major Adverse Cardiac Events (MACE)

    Time frame: 6 Months

  2. Major Adverse Cardiac Events

    Time frame: 12 Months

  3. Late Lumen Loss

    Time frame: 9 Months

Secondary outcomes

  1. QCA derived parameters

    Time frame: 9 Months

    Late Loss, Restenosis Rate, % Diameter Stenosis & Minimum Lumen Diameter

  2. Major Adverse Coronary Events

    Time frame: 24, 36, 48 & 60 Months

    Major Adverse Coronary Events - Combined events consisting of death, myocardial infarction and Target Lesion Revascularization

  3. TLR

    Time frame: 12,24,36,48 & 60 Months

    Target Lesion Revascularization

  4. TVR

    Time frame: 12,24,36,48 & 60 Months

    Target Vessel Revascularization

  5. TVF

    Time frame: 12, 24, 36, 48 & 60 Month

    Target Vessel Failure

  6. Acute Procedural Success

    Time frame: Day 0

    The percentage of patients meeting the Acute Technical Success criteria and the procedure results in a residual stenosis of <50 percent with no immediate (in-hospital) MACE.

  7. Acute Technical Success

    Time frame: Day 0

    The percentage of patients with successful delivery and deployment of the scaffold in the intended lesion without device related complications.

  8. Clinical Procedural Success

    Time frame: 30 Days

    The percentage of patients meeting the Acute Procedural Success criteria with no occurrence of a MACE event through 30 days.

Sponsors and collaborators

Lead sponsor

REVA Medical, Inc.

Industry

Registry information

Official study title

RESTORE II Trial: Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold

Acronym: RESTORE II

Important dates

Study start
2013
Primary completion
2014
Study completion
2019
First posted
May 3, 2013
Registry last updated
Mar 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.